UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 9, 2025 ImmuCell Corporation | (Exact name of registrant as specified in its charter) | | | | --- | --- | --- | | DE | 001-12934 | 01-0382980 | | (State or other jurisdiction | (Commission File Number) | (IRS Employer | | of incorporation) | | Identification No.) | | 56 Evergreen Drive P ...

PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2024. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaud ...

PORTLAND, Maine, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the fourth quarter and full year ended December 31, 2024. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaud ...

Zacks Investment Research has recently initiated the coverage of ImmuCell Corporation (ICCC) with a “Neutral” recommendation. The Portland, ME-based company, founded in 1982, specializes in scientifically proven animal health products aimed at improving the health and productivity of dairy and beef cattle. This balanced outlook reflects the company's potential and the risks inherent in its operations and market environment.ImmuCell's market-leading First Defense product line stands out in the $75-million sc ...

Shares of ImmuCell Corporation (ICCC) have lost 3% since the company reported earnings for the third quarter of 2024. Notably, the S&P 500 index declined 2% in the same period. Over the past month, ICCC stock has seen a 0.3% decline against the S&P 500's 0.7% rise, highlighting relatively underwhelming performance amid broader market strength.Q3 Sales & Earnings PerformanceThe company reported third-quarter 2024 earnings per diluted share of 9 cents, down from 12 cents in the prior-year quarter.ImmuCell's p ...

ImmuCell Corporation (NASDAQ:ICCC) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Company Participants Joe Diaz - Lytham Partners Michael Brigham - President and CEO Conference Call Participants George Melas - MKH Management Operator Good morning and welcome to ImmuCell Corporation Reports Third Quarter September 30, 2024, Unaudited Financial Results Conference Call. All participants will be in listen-only mode. After today’s presentation, there will be an opportunity to ask questions. Please ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware 01-0382980 (State of Incorporation) (I.R.S. Employer Identification No.) Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, $0.10 par value per share ICCC The Nasdaq Capital Market FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 001-12934 (Commission file number) ImmuCell Corporation ( ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 8, 2024 ImmuCell Corporation | --- | --- | |-----------------------------------------------------------------------------------------|-----------------------| | (Exact name of registrant as specified in its charter) \nDE 001-12934 | 01-0382980 | | (State or other jurisdiction (Commission ...

PORTLAND, Maine, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2024 after the market closes on Wednesday, November 13, 2024. The Company is planning to host a conference call the next morning ...

PORTLAND, Maine, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2024, which ended September 30, 2024. Preliminary, Unaudited Total Sales Results: 2024 2023 $ Increase % Increase During the Three-M ...